Conversely, treatment of mice fed a HFD with a PPARα agonist have reduced hepatic steatosis and inflammation, further highlighting the critical role for PPARα in hepatic fatty acid catabolism. The gene discussed is PPARA; the disease is Hepatic steatosis.